Contact
Real-World Evidence

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi

Download Report

Chauhan A, Samnaliev M, Ken-Opurum J, Sai Srinivas S, Mehta AM, Dex T, Charland S, Revel A, Preblick R

About 37.3 million people in the US have Type 2 Diabetes Mellitus (T2DM), accounting for more than 95% of all diabetes cases. The objective of this study was to identify two real-world cohorts of individuals with T2DM from an integrated claims and EHR database who meet the criteria for treatment with iGlarLixi and apply a Monte Carlo simulation to mirror the treatment arms in the LixiLan-O and LixiLan-L trials, thus evaluating the clinical benefits of iGlarLixi in these patients.

Contact us at connect@axtria.com with any questions.
Advanced Analytics HEOR/RWE Real-World Evidence RWE
Download Report - Treating Patients With Type 2 Diabetes Mellitus


Download Report
Complete the brief form to download the white paper

Recommended insights

Treating Patients With Type 2 Diabetes Mellitus

Case Study

Long-Term Partnership Helps Advance Real World Evidence in Regulatory and Clinical Decision-Making
Learn more
Treating Patients With Type 2 Diabetes Mellitus

White Paper

Digital Twins: A Fit-for-Purpose Solution to Elevate Clinical Trial Power and Efficiency
Learn more
Treating Patients With Type 2 Diabetes Mellitus

Article

Evidence at the Forefront: Why Integrated Evidence Planning is Essential for Biopharma Innovation
Learn more